Molecular Determinants of Ethionamide Resistance in Clinical Isolates of Mycobacterium tuberculosis.

ABSTRACT:

Background

Ethionamide and prothionamide are now included in group C of the WHO recommended drugs for the treatment of tuberculosis resistant to rifampicin and multidrug-resistant tuberculosis. The clinical relevance of ethionamide and prothionamide has increased with the wide spread of resistant tuberculosis.

Methods

We retrospectively analyzed 349 clinical isolates obtained between 2016 and 2020. The susceptibility to ethionamide was tested using both the Bactec^TM MGIT^TM 960 system and the Sensititre^TM MYCOTB plate.

Results

The MIC of ethionamide increases with the total resistance of the isolates in a row from susceptible to XDR strains. A significant part of the isolates have a MIC below the breakpoint: 25%, 36%, and 50% for XDR, p

SUBMITTER: Ushtanit A 

PROVIDER: S-EPMC8868424 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature